# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cramer recommends selling PBR, buying EPD, LNG, RXRX, and CASY. Criticisms of AVGO's licensing changes dismissed. PBR and C...
On Thursday, Cathie Wood’s Ark Invest made significant trades involving Coinbase Global, Inc. (NASDAQ:COIN), Palantir Technolog...
Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $17 price target.
Nvidia announces partnerships with J&J and GE Healthcare to integrate generative AI into surgery and medical imaging at GTC...
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported b...